Summer Sale
50% off Premium Yearly
TSE:JWEL
Jamieson Wellness (JWEL.TO)
Financials 
Technical Analysis 
He sold it after a recent disappointing earnings report (lowered their guidance a lot). After all, they're not in a cyclical business. Their acquisition of a Chinese company was interesting, though the structure was unusual--they bought $100 million in preferred shares with warrants but no dividend and took a minority share in the Chinese business. That was the right move in the Chinese market. Otherwise, JWEL's fundamentals didn't impress him. The stock isn't getting much love these days.
Stockchase Discover
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS at 34 cents that beat estimates by 2%. Sales of $112.3M were reported. Generally a good quarter. The focus on post covid health trends continue to be a tailwind. Attractive here. Unlock Premium - Try 5i Free
Stockchase InsightsBilly Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues beat street estimates by 4%. EBITDA was 2% better at $29M. It is trading at 26x earnings, which is reasonably considering the high growth expectations. There are competitors but they have strong market share. A higher risk buy for growth and some income. Unlock Premium - Try 5i Free
Stockchase Insights
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free
Stockchase InsightsBilly Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free
Stockchase Insights'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Jamieson Wellness (JWEL.TO) Frequently Asked Questions
What is Jamieson Wellness stock symbol?
Jamieson Wellness is a Canadian stock, trading under the symbol JWEL.TO (previously JWEL-T on Stockchase) on the Toronto Stock Exchange (JWEL-CT). It is usually referred to as TSX:JWEL or JWEL.TO
Is Jamieson Wellness a buy or a sell?
In the last year, no analyst issued a Buy, Sell, or Hold rating on JWEL.TO (previously JWEL-T on Stockchase) on Stockchase. Read the latest expert commentary for Jamieson Wellness.
Is Jamieson Wellness a good investment or a top pick?
Jamieson Wellness was recommended as a Top Pick by Stockchase Insights on 2020-11-11. Read the latest stock experts ratings for Jamieson Wellness.
Why is Jamieson Wellness stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Jamieson Wellness.
Is Jamieson Wellness worth watching?
Jamieson Wellness is followed by 88 investors on Stockchase and is a trending stock that is worth watching.
What is Jamieson Wellness stock price?
On 2026-06-19, Jamieson Wellness (JWEL.TO) stock closed at a price of $36.48.
Canada's #1 brand in its sector, has 25% market share. Went public 6-7 years ago, and increased sales and profits every year. US acquisition should accelerate growth. Now controls direct distribution in China. Cheaper than ever at 18x earnings, but growth prospects are better than ever. High margin, high quality, steady. Great entry point. Yield is 2.32%.
(Analysts’ price target is $43.53)